Why the FDA breakthrough pathway matters for Laguna Diagnostics’ psychiatric test
Psychiatry needs objective diagnostics. Laguna Diagnostics now faces the harder test: proving mRNA biomarkers can scale in real care.
Medical Devices & Diagnostics
Pharma & Biotech
FDA approval of milsaperidone puts Vanda Pharmaceuticals into crowded bipolar I disorder and schizophrenia markets
FDA approves milsaperidone for bipolar I disorder and schizophrenia. Explore what this means for psychiatry, competition, and Vanda Pharmaceuticals’ strategy.